Biopharmaceutical Engineering Major, Division of Applied Bioengineering, College of Engineering, Dong-eui University, Busan 47340, Republic of Korea.
Department of Biopharmaceutics, Dong-eui University Graduate School, Busan 47340, Republic of Korea.
J Microbiol Biotechnol. 2022 Jul 28;32(7):918-926. doi: 10.4014/jmb.2205.05012. Epub 2022 Jul 1.
Proteins related to DNA replication have been proposed as cancer biomarkers and targets for anticancer agents. Among them, minichromosome maintenance (MCM) proteins, often overexpressed in various cancer cells, are recognized both as notable biomarkers for cancer diagnosis and as targets for cancer treatment. Here, we investigated the activity of cedrol, a single compound isolated from , in reducing the expression of MCM proteins in human lung carcinoma A549 cells. Remarkably, cedrol also strongly inhibited the expression of all other MCM protein family members in A549 cells. Moreover, cedrol treatment reduced cell viability in A549 cells, accompanied by cell cycle arrest at the G1 phase, and enhanced apoptosis. Taken together, this study broadens our understanding of how cedrol executes its anticancer activity while demonstrating that cedrol has potential application in the treatment of human lung cancer as an inhibitor of MCM proteins.
已提出与 DNA 复制相关的蛋白质作为癌症生物标志物和抗癌药物的靶标。其中,微染色体维持(MCM)蛋白在各种癌细胞中常过度表达,它们不仅被认为是癌症诊断的显著生物标志物,也是癌症治疗的靶标。在这里,我们研究了从 中分离出的单一化合物雪松醇降低人肺癌 A549 细胞中 MCM 蛋白表达的活性。值得注意的是,雪松醇还强烈抑制 A549 细胞中所有其他 MCM 蛋白家族成员的表达。此外,雪松醇处理降低了 A549 细胞的活力,伴随着细胞周期停滞在 G1 期,并增强了细胞凋亡。总之,这项研究拓宽了我们对雪松醇如何发挥其抗癌活性的理解,同时表明雪松醇作为 MCM 蛋白抑制剂在治疗人类肺癌方面具有潜在的应用。